Quantcast

TomoTherapy Concludes Treatment Quality Challenge

July 1, 2008

TomoTherapy Incorporated (NASDAQ:TOMO), maker of the TomoTherapy(R) Hi-Art(R) treatment system for advanced radiation therapy, today announced the close of its Treatment Quality Challenge. The company had offered $250,000 to any U.S. cancer center that could surpass the quality of a helical TomoTherapy(SM) treatment plan using a single-rotation Varian RapidArc(TM) plan delivered in two minutes or less. The three-month program ended on June 30, 2008, without a single entry.

“For TomoTherapy, the Challenge was a definite success,” said Del Coufal, TomoTherapy’s vice president of marketing. “It generated strong support from customers and gave us the opportunity to let new audiences know that our focus is, first and foremost, on improving the quality of cancer care.”

Since its clinical introduction in 2003, the TomoTherapy Hi-Art treatment system has emerged as the gold standard for image-guided, intensity-modulated radiation therapy (IG-IMRT). The system is unique among linear accelerators because it was built on a CT scanner platform, thereby integrating true CT imaging with continuous, 360-degree delivery of targeted radiation.

“Our platform has changed the way cancer centers think about radiation therapy,” said Fred Robertson, CEO of TomoTherapy. “It’s no longer just about patient throughput as a function of beam-on time. It’s about efficiencies to be gained across the clinical workflow with a single integrated system. And, it’s about new opportunities to enhance the quality of life for cancer patients.”

Robertson points to TomoTherapy’s CTrue(TM) imaging: “More than 95 percent of patients who undergo treatment on our machines are CT scanned before each and every daily treatment. Though it does add minimal time to the process, our customers use this feature because it improves accuracy–and they can still treat more than 30 patients per day. This unique combination of unmatched quality and overall system efficiency is the true power of our platform.”

As the Hi-Art system continues to mature, Coufal said there are several industry-leading innovations on the horizon. ‘We expect to see improvement in overall patient throughput with an exciting new product moving through our development pipeline. It will be especially useful for the more routine case types. With this and future advances, it is clear that our next-generation, ring gantry platform can offer all the flexibility cancer centers demand.”

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

(C)2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, CTrue, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.




comments powered by Disqus